The potential of targeting malignant stem cells as a treatment for leukemia

University of Rochester School of Medicine, 601 Elmwood Ave, Box 703 Rochester, NY 14642, USA.
Future Oncology (Impact Factor: 2.48). 05/2005; 1(2):205-7. DOI: 10.1517/14796694.1.2.205
Source: PubMed


Malignant stem cells have recently been described as the source of several types of human cancer. These unique cell types are typically rare and possess properties that are distinct from most other tumor cells. In leukemia, the natural properties of cancer stem cells indicate that current chemotherapy drugs will not be effective. Consequently, new strategies are required that specifically and preferentially target the cancer stem cell population, whilst sparing normal stem cells. This perspective article summarizes recent findings in the leukemia stem cell field and discusses new directions for therapy.

1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukemia (AML) in children encompasses a distinctive set of diseases with special considerations related to age, drug metabolism, and both short- and long-term sequelae. This chapter will emphasize inherited syndromes that predispose to leukemogenesis, development of secondary AML, and the roles of dose intensification and stem cell transplantation in the ongoing improvement in cure rates. The importance of risk stratification in the design of clinical trials, based on cytogenetic and molecular characteristics, is critical to optimizing the balance between curability, quality of life, and minimization of long-term sequelae for children with AML.
    12/2006: pages 345-372;
  • [Show abstract] [Hide abstract]
    ABSTRACT: 5-Aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation, is an effective agent for the treatment of leukemia. The aim of this study was to investigate the antileukemic activity of this epigenetic agent in combination with genistein, a nontoxic isoflavone with chemopreventive activity. The combined treatment produced a synergistic loss of clonogenicity in human myeloid (HL-60) and lymphoid (MOLT-3) leukemic cell lines. Genistein alone showed a significant antileukemic activity against murine 5-AZA-CdR-resistant cells, and this effect was enhanced when used in combination with 5-AZA-CdR. The combined treatment also produced a synergistic increase in life span of mice with L1210 leukemia. These results suggest that genistein may have the potential to increase the clinical efficacy of 5-AZA-CdR for the treatment of leukemia.
    Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics 02/2008; 17(5):223-30. DOI:10.3727/096504008786111356 · 1.06 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Object: Tumor-initiating cells are uniquely resilient to current treatment modalities and play an important role in tumor resistance and recurrence. The lack of specific tumor-initiating cell markers to identify and target these cells presents a major obstacle to effective directed therapy. Methods: To identify tumor-initiating cell markers in primary brain tumors, the authors compared the proteomes of glioma tumor-initiating cells to their differentiated progeny using a novel, nongel/shotgun-based, multidimensional liquid-chromatography protein separation technique. An in vivo xenograft model was used to demonstrate the tumorigenic and stem cell properties of these cells. Western blot and immunofluorescence analyses were used to confirm findings of upregulated ciliary neurotrophic factor receptor subunit-α (CNTFRα) in undifferentiated tumor-initiating cells and gliomas of increasing tumor grade. Sequencing of the CNTFRα coding regions was performed for mutation analysis. Finally, antibody-dependent cell-mediated cytotoxicity was used to establish the role of CNTFRα as a potential immunotherapeutic target. Results: Ciliary neurotrophic factor receptor subunit-α expression was increased in tumor-initiating cells and was decreased in the cells' differentiated progeny, and expression levels increased with glioma grade. Mutations of CNTFRα are not common in gliomas. Functional studies using CNTF treatment in glioma tumor-initiating cells showed induction of differentiation through the CNTFRα pathway. Treatment with anti-CNTFRα antibody resulted in increased antibody-dependent cell-mediated cytotoxicity in CNTFRα expressing DAOY cells but not in cell lines that lack CNTFRα. Conclusions: These data indicate that CNTFRα plays a role in the formation or maintenance of tumor-initiating cells in gliomas, is a marker that correlates with histological grade, may underlie treatment resistance in some cases, and is a potential therapeutic target.
    Journal of Neurosurgery 10/2012; 117(6). DOI:10.3171/2012.9.JNS1212 · 3.74 Impact Factor

Similar Publications